Is Bradykinin legal in the United Kingdom?

A 9 amino acid inflammatory mediator, not a therapy. It is the reason ACE inhibitors cause cough and angioedema, and human forearm and nerve studies have measured what it does; there is no clinical use for administering it.

Bradykinin is a 9 amino acid peptide, sequence RPPGFSPFR, released from kininogen by kallikrein enzymes during inflammation and tissue injury. It dilates blood vessels, increases vascular permeability and sensitises pain-carrying nerves.

Mechanism: In humans, bradykinin acts at two G protein-coupled receptors: B2, which is present constitutively, and B1, which is induced by inflammation. B2 activation on endothelium releases nitric oxide and prostacyclin, producing vasodilation and increased permeability; on nociceptors it lowers the threshold for firing.

Regulatory history: Not an approved drug. Bradykinin is an endogenous mediator and a laboratory reagent; no bradykinin product appeared in the Drugs@FDA checks run for this batch. The approved medicine acting on this system is the B2 receptor antagonist icatibant.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for Bradykinin at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.